RFK Jr. Asserts Insufficient Evidence Linking Tylenol to Autism
Robert F. Kennedy Jr., the Health Secretary, addressed concerns regarding the use of Tylenol during pregnancy. He stated that while caution is advised, there is insufficient evidence to establish a definitive link between Tylenol and autism.
RFK Jr. on Tylenol and Autism
On October 29, Kennedy emphasized that current studies do not provide enough proof connecting Tylenol use with autism. His remarks came closely after President Donald Trump suggested that U.S. health officials might recommend limiting the painkiller’s use among pregnant women and young children.
Texas Lawsuit Against Kenvue
On October 28, the state of Texas filed a lawsuit against Kenvue, the manufacturer of Tylenol. The lawsuit alleges that Kenvue has concealed critical data regarding potential health risks associated with the drug.
“The causative association between Tylenol and autism is not sufficient to claim it definitively causes the disorder,” Kennedy noted. However, he reiterated that the drug should be taken cautiously during pregnancy.
Autism Statistics in the U.S.
According to a report from the Centers for Disease Control and Prevention (CDC), the prevalence of autism diagnoses among children has grown. In 2022, 1 in 31 children received an autism diagnosis by age 8. This is an increase from 1 in 36 in 2020 and marks a fivefold rise since the year 2000.
- 2022: 1 in 31 children diagnosed with autism
- 2020: 1 in 36 children diagnosed with autism
- Autism prevalence among boys: 1 in 20
Mixed Responses from Officials
Kennedy’s assessment caused some concern among medical professionals. While he acknowledged the lack of clear evidence linking Tylenol and autism, he insisted that people who take it during pregnancy should do so only when absolutely necessary. “It’s irresponsible to take the medication unless required,” he said during an October Cabinet meeting with Trump.
Additionally, the FDA announced on September 22 that it would be reviewing safety labels for medications containing acetaminophen. This move aligns with ongoing concerns regarding potential adverse neurodevelopmental outcomes associated with its use during pregnancy.
Kenvue’s Position
Kenvue has consistently defended the safety of Tylenol, asserting there is no scientific basis for the claims linking their product to autism. They have expressed concerns that such accusations could jeopardize maternal health.
In a statement, Kenvue reiterated, “We support consulting healthcare professionals before taking acetaminophen, which is the guidance our Tylenol label provides. There is no definitive link between acetaminophen and autism.”
Following Kennedy’s comments, Kenvue’s stock fell by 1.4% on October 29, reflecting investor concerns.
